Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:20 ET
|
Organovo, Inc.
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate...
Organovo Announces Postponement of Annual Meeting of Stockholders
September 06, 2022 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate...
Organovo Achieves 3D Tissue Model for Crohn’s Disease
May 17, 2022 08:05 ET
|
Organovo, Inc.
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel...
UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
March 01, 2022 08:05 ET
|
Organovo, Inc.
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO (OTCPK: CLLKF, Nasdaq Stockholm: BICO.ST) announced they have reached agreement on a broad license for...
Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
February 23, 2022 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to...
Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2022 16:00 ET
|
Organovo, Inc.
SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo”), today announced that it has granted a stock option to purchase 50,000 shares of common stock to one...
Organovo Welcomes New Sr. Vice President of Strategy and Business Development
February 18, 2022 13:00 ET
|
Organovo, Inc.
SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using 3D...
Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents
February 02, 2022 12:00 ET
|
Organovo, Inc.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced that two of its patents have withstood a patent challenge, and the company provided guidance on...
Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk
January 10, 2022 12:00 ET
|
Organovo, Inc.
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today released its first detailed response to the lawsuit Cellink (NASDAQ Stockholm: BICO) filed against it in...
Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022
November 30, 2021 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today provided a business overview and progress update, and announced it is on track to establish its first...